Rising Prevalence Of Cancer Fueling The Growth Of The Market Due To Increasing Patient Demand For Personalized And Precise Treatment Strategies: Strategic Insights Driving Molecular Tumor Board Solutions Market Momentum in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Molecular Tumor Board Solutions Market Size By 2025?
In recent years, the market size for molecular tumor board solutions has seen a fast-paced expansion. It is expected to increase from $1.34 billion in 2024 to $1.53 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.9%. The growth observed in the historical period is likely due to the rising uptake of genomic profiling, an increased need for precision oncology, heightened awareness of molecular diagnostics, the growth of cancer research initiatives, and more partnerships between hospitals and biotech companies.

How Big Is the Molecular Tumor Board Solutions Market Size Expected to Grow by 2029?
Anticipated to experience swift expansion within the coming years, the molecular tumor board solutions market size is projected to reach $2.53 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to the market's growth during this forecast period include the increasing need for multidisciplinary tumor boards, developments and expansions in cloud-based molecular data platforms, greater regulatory backing for genomic testing, more focus on patient-focused oncology care, and a surge in cancer cases. Prime trends for the period incorporate advancements in genomic sequencing tools, further investment into molecular solutions research and development, improvements in clinical decision support software, progression in data analytics and visualization, and the amalgamation of machine learning into treatment recommendations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/molecular-tumor-board-solutions-global-market-report

Which Key Market Drivers Powering Molecular Tumor Board Solutions Market Expansion and Growth?
The growth of the molecular tumor board solutions market is set to be driven by the escalating rates of cancer. Cancer, a set of diseases marked by unregulated growth and the spread of abnormal cells, has seen its prevalence rise due to lifestyle factors such as improper diet, smoking, lack of physical activity, and overconsumption of alcohol. Molecular tumor board solutions contribute to cancer treatment regimens by offering specialist, multidisciplinary assessments of the genetic and clinical data of patients, which facilitates the personalization of treatment plans. These solutions augment clinical decision-making by combining molecular profiling with AI-generated insights, thereby enhancing patient outcomes and the accuracy of treatment. For example, in October 2024, the National Health Service, a government department in the UK, reported a 5% increase in new cancer diagnoses, from 329,664 in 2021 to 346,217 in 2022, equating to an average of 948 new cases each day. Thus, the increasing incidences of cancer are propelling the expansion of the molecular tumor board solutions market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28274&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Molecular Tumor Board Solutions Market?
Leading firms in the molecular tumor board solutions market are concentrating on the creation of novel solutions, like molecular profiling tests, to increase the precision and efficiency of cancer diagnosis and treatment strategies. Molecular profiling tests are diagnostic tools that examine the genetic and molecular attributes of a tumor to assist in making individualized cancer treatment choices. For example, Guardant Health Inc., an American biotech and precision oncology company, unveiled Guardant360 Tissue in April 2025. This is a pioneering molecular profiling test for tumor tissue that incorporates multiple analyses, including the examination of DNA, RNA, artificial intelligence-driven PD-L1, and methylation data across the genome. This sophisticated test, powered by the Guardant Infinity smart liquid biopsy platform, provides a broader and more complex view of cancer, thereby allowing for more precise tumor classification and subtyping. Offering results in less than two weeks, Guardant360 Tissue is supported by Medicare for qualifying patients and seeks to boost precision oncology by supplying deeper insights to inform treatment choices, such as therapy involving poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies.

What Are the Emerging Segments in the Molecular Tumor Board Solutions Market?
The molecular tumor board solutions market covered in this report is segmented as

1) By Component: Software, Services
2) By Deployment Mode: On-Premises, Cloud-Based
3) By Application: Clinical Decision Support, Genomic Data Interpretation, Patient Management, Other Applications
4) By End-User: Hospitals, Cancer Centers, Research Institutes, Other End-Users

Subsegments:
1) By Software: Clinical Decision Support, Data Analytics, Reporting And Visualization, Integration Platforms
2) By Services: Consulting, Implementation, Training And Support, Maintenance And Upgrades

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28274&type=smp

Who Are the Global Leaders in the Molecular Tumor Board Solutions Market?
Major companies operating in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, and CureMatch Inc.

Which are the Top Profitable Regional Markets for the Molecular Tumor Board Solutions Industry?
North America was the largest region in the molecular tumor board solutions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular tumor board solutions report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28274

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.